Last edition
News about " Overall Response Rate"
BMS Reports Positive EXCALIBER-RRMM Results for Zenbexus in Multiple Myeloma
Bristol Myers Squibb reported phase 3 EXCALIBER-RRMM results showing higher MRD-negative complete response rates with Zenbexus plus daratumumab and dexamethasone.
Overall Response Rate | 28/09/2026 | By News Bureau | 187
Bristol Myers Squibb’s arlo-cel demonstrated statistically significant and clinically meaningful responses in patients with quadruple-class exposed relapsed and refractory multiple myeloma.
Overall Response Rate | 09/09/2026 | By News Bureau | 164
BioInvent's BI-1808 Receives FDA Fast Track Designation for Ovarian Cancer
BioInvent’s BI-1808 has received FDA Fast Track Designation for ovarian cancer, supporting accelerated development of the investigational anti-TNFR2 therapy in combination with pembrolizumab.
Overall Response Rate | 11/08/2026 | By News Bureau | 108
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy